Investor Presentaiton

Oncology Opdivo Opdualag TIGIT Bispecific DGK Inhibitor AR LDD Addressing high unmet medical need in Oncology Asset OPDIVO (nivolumab) Approved 26 approvals across 11 tumors Registrational+ 9 ongoing trials Exploratory/PoC Studies* Opdualag repotrectinib² subcutaneous nivolumab¹ AR LDD DGK Inhibitor farletuzumab ecteribulin TIGIT Bispecific 1L melanoma Adj. melanoma 2L/3L+ MSS CRC . 1L melanoma SC • 1L/2L+ HCC 1L NSCLC 1L ROS1+ NSCLC U.S. All Q2W & Q4W indications (bridging from 2L RCC) NTRK Pan Tumor 2L+ mCRPC Solid tumors NSCLC & ovarian NSCLC & gastric 1. U.S. Regulatory path opens up indications with Q2W and Q4W dose including melanoma, CRC, HCC, 2L NSCLC, UC, ESCC, & Gastric 2. U.S. PDUFA: November 27, 2023 Bristol Myers Squibb † ongoing or initiating 2023/2024 Not for Product Promotional Use 94

View entire presentation